Skip to main content
. Author manuscript; available in PMC: 2012 Jan 14.
Published in final edited form as: AIDS. 2011 Jan 14;25(2):211–220. doi: 10.1097/QAD.0b013e328340fdf8

Figure 2. Health and Cost Outcomes for First-line Antiretroviral Strategies.

Figure 2

Lifetime discounted costs in 2009 US dollars and quality-adjusted life expectancy for the five first-line antiretroviral regimens. Strategies that could be considered cost-effective are connected with a line that indicates the incremental cost-effectiveness ration of moving from one strategy to the next. Two strategies – stavudine/lamivudine/nevirapine and zidovudine/lamivudine/efavirenz – are unlikely to be cost effective. The results support the decision to exclude stavudine/lamivudine/nevirapine from the list of recommended regimens, and suggest an important role for tenofovir-based regimens.